AKT1 and cancer: There are distinct transcriptional control mechanisms of PD-L1 in cancer, including signaling pathways such as RAS/RAF/MEK/MAPK-ERK, PI3K/PTEN (a negative regulator of PI3K)/Akt/mTOR, and JAK/STAT.